Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 As a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)

Next Previous
Trial Profile

A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 As a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briquilimab (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Jasper Therapeutics

Most Recent Events

  • 27 Feb 2025 Status changed from recruiting to discontinued.
  • 07 Nov 2024 Results presented in the Jasper Therapeutics financial media release.
  • 07 Nov 2024 According to a Jasper Therapeutics media release, based on result Jasper has elected to discontinue development in the indication. Data from the study are expected to be presented at a future medical conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top